| P2093 | author name string | M Hartmann | |
| | J Brust | |
| | J A Rump | |
| | H Klinker | |
| | D Schuster | |
| | D Petzoldt | |
| | M Procaccianti | |
| | F Mosthaf | |
| P2860 | cites work | Sex differences in nevirapine rash | Q31704898 |
| | Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis | Q34093134 |
| | Efavirenz-induced skin eruption and successful desensitization | Q40586739 |
| | Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients | Q43461248 |
| | Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients | Q43820402 |
| | Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study | Q43945659 |
| | Long-term safety and efficacy of nevirapine tolerance induction. | Q43982208 |
| | Prospective evaluation of risk factors of cutaneous drug reactions to sulfonamides in patients with AIDS. | Q44037356 |
| | Cutaneous disease and drug reactions in HIV infection | Q44111761 |
| | Incidence and risk factors for nevirapine-associated rash | Q44550880 |
| | Exanthema simulating measles without measles virus? Allergic reaction to a non-nucleoside reverse transcriptase inhibitor in an HIV infected boy treated with HAART | Q44564375 |
| | Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals | Q44727378 |
| | Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study | Q44849439 |
| | Incidence of rash and discontinuation of nevirapine using two different escalating initial doses | Q45013023 |
| | Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection | Q45751686 |
| | Comparison of efavirenz and nevirapine in HIV-infected patients (NEEF Cohort). | Q46559774 |
| | Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels ( | Q56897804 |
| | Hypersensitivity syndrome associated with efavirenz therapy | Q73321205 |
| | Nevirapine-associated Stevens-Johnson syndrome | Q74282325 |
| | Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash? | Q74306510 |
| | DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy | Q77595515 |
| P433 | issue | 9 | |
| P407 | language of work or name | German | Q188 |
| P921 | main subject | nevirapine | Q263713 |
| | efavirenz | Q422645 |
| P304 | page(s) | 847-853 | |
| P577 | publication date | 2005-09-01 | |
| P1433 | published in | Die Dermatologie | Q15756740 |
| P1476 | title | Rashes in HIV-infected patients undergoing therapy with nevirapine or efavirenz | |
| P478 | volume | 56 | |